<DOC>
	<DOCNO>NCT02417662</DOCNO>
	<brief_summary>The trial ass addition stereotactic ablative radiotherapy ( SABR ) standard chemotherapy patient oligometastatic non-small cell lung cancer . Patients randomise receive either standard treatment alone ( platinum-based doublet chemotherapy ) standard treatment conventional radiotherapy ( RT ) SABR .</brief_summary>
	<brief_title>Stereotactic Ablative Radiotherapy Oligometastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>SARON confirmatory phase III study examine efficacy safety stereotactic ablative radiotherapy ( SABR ) conventional radiotherapy ( RT ) alongside standard chemotherapy patient oligometastatic non-small cell lung cancer . Current treatment group patient platinum-based doublet chemotherapy alone . There sufficient evidence regard safety SABR , effect local control possible impact overall survival . This trial examine overall survival , progression free survival local control , well toxicity , feasibility , patient report outcome health resource use . There feasibility analysis perform 50 patient randomise . This assess practicality achieve recruitment target , logistics deliver experimental treatment potential contamination ( patient may seek SABR outside trial randomise non SABR arm ) . There also parallel thoracic SABR safety feasibility study recruitment treatment 20 patient thoracic metastasis . This multicentre randomise phase III study base patient oligometastatic NSCLC . Trial arm : Control Arm : standard treatment alone ( platinum-based doublet chemotherapy ) Experimental Arm : standard treatment plus radical RT primary SABR and/or SRS metastasis</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically cytologically confirm NSCLC . 2 . Negative unknown EGFR ALK mutation ( EGFR test mandatory ALK testing perform part local policy ) . 3 . Staging FDG PETCT whole body scan MRI brain CT brain IV contrast . 4 . Patient present synchronous primary disease oligometastatic disease . 5 . Patient deem fit receive least four cycle platinumbased doublet chemotherapy , cisplatin carboplatin , accord local guideline assessment . 6 . Patient deem fit receive conventional RT SABR/SRS accord local guideline assessment . 7 . Primary tumour suitable radical RT ( either conventional RT SABR/SRS ) . 8 . Between one three metastatic lesion , assessable accord RECIST v1.1 suitable SABR/SRS ( one site metastases primary tumour need measurable accord RECIST v1.1 ) . Note : If brain metastasis present , large lesion must less 3cm maximum diameter time randomisation . The second lesion must 2cm . 9 . Acceptable lung function radical lung radiotherapy . 10 . No relevant comorbidities , include pulmonary fibrosis connective tissue disorder . 11 . ECOG performance status 0 1 time registration ( ECOG 02 randomisation ) . Exclusion criteria 1 . Patient palliative radiotherapy tumour site prior registration and/or require palliative radiotherapy prior randomisation . 2 . Patient receive previous treatment NSCLC malignancy . 3 . Patients present brain metastasis sit extra cranial metastatic disease i.e . presence 2 brain metastasis exclusion criterion . 4 . Brain metastasis within brainstem . 5 . Metastasis sit normal radiotherapy constraint meet . 6 . Metastasis previously irradiate area 7 . Patients three site disease prior trial registration . 8 . Primary tumour metastasis cause direct invasion high clinical suspicion direct invasion wall major blood vessel . 9 . Malignant pleural pericardial effusion . 10 . Patients bilateral adrenal metastasis . 11 . Stage III disease even extensive nodal disease . 12 . History prior malignant tumour likely interfere protocol treatment comparison , unless patient without evidence disease least 3 year tumour nonmelanoma skin tumour early cervical cancer . 13 . Leptomeningeal disease . 14 . Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Stereotactic Ablative Radiotherapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Randomised</keyword>
	<keyword>Controlled</keyword>
	<keyword>Oligometastatic</keyword>
</DOC>